Q32 Bio's Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients.
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment w ...
A new Northwestern Medicine study has uncovered how a key immunoregulatory receptor plays an unexpected dual role in ...
Melatonin is best known for helping us sleep. But a new study suggests it might have another surprising use: easing muscle ...
Three major studies showed that finerenone could provide kidney and CV benefits for a wider range of patients with chronic ...
With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...
The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, backing up the biotech’s ...
Fascinating nervous system imaging reveals previously unseen obesity-related nerve damage in mice and humans — and some of it ...
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily ...
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results